沃森生物
(300142)
| 流通市值：219.70亿 | | | 总市值：222.79亿 |
| 流通股本：15.77亿 | | | 总股本：15.99亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 443,848,309.81 | 2,418,234,933.46 | 1,718,807,933.37 | 1,154,212,387 |
| 营业收入 | 443,848,309.81 | 2,418,234,933.46 | 1,718,807,933.37 | 1,154,212,387 |
| 二、营业总成本 | 406,874,077.19 | 2,107,110,191.82 | 1,488,300,078.09 | 975,738,044.24 |
| 营业成本 | 139,961,391.93 | 615,248,686.86 | 486,527,451.46 | 343,069,354.13 |
| 税金及附加 | 4,826,597.58 | 20,220,884.37 | 14,138,622.6 | 9,481,632.39 |
| 销售费用 | 154,161,138.34 | 854,091,902.74 | 563,141,435.19 | 376,601,671.18 |
| 管理费用 | 60,530,231.72 | 392,125,961.18 | 270,625,620.92 | 170,282,241.23 |
| 研发费用 | 43,803,178.56 | 291,877,572.4 | 215,702,777.83 | 120,802,796.56 |
| 财务费用 | 3,591,539.06 | -66,454,815.73 | -61,835,829.91 | -44,499,651.25 |
| 其中:利息费用 | 7,056,519.82 | -2,217,643.94 | -3,453,846.24 | -927,807.93 |
| 其中:利息收入 | 6,125,280 | 67,238,667.68 | 58,906,084.59 | 43,142,415.6 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -19,057,700 | 29,676,000 | 91,800,300 | 13,422,300 |
| 加:投资收益 | -238,170.48 | 2,537,266.79 | 2,783,580.43 | -486,057.34 |
| 资产处置收益 | -12,864.06 | 81,071.48 | 175,200.11 | 130,387.03 |
| 资产减值损失(新) | -13,345,508.8 | -102,730,882.64 | -122,375,694.4 | -131,388,229.06 |
| 信用减值损失(新) | 102,668,329.38 | -148,933,720.99 | -85,226,824.24 | -61,330,925.64 |
| 其他收益 | 24,066,538.7 | 96,194,833.83 | 22,689,212.57 | 15,106,458.84 |
| 四、营业利润 | 131,054,857.36 | 187,949,310.11 | 140,353,629.75 | 13,928,276.59 |
| 加:营业外收入 | 15,209.44 | 731,624.75 | 716,556.87 | 682,363.21 |
| 减:营业外支出 | 2,131,941.21 | 22,568,541.63 | 4,791,569.95 | 2,568,147.84 |
| 五、利润总额 | 128,938,125.59 | 166,112,393.23 | 136,278,616.67 | 12,042,491.96 |
| 减:所得税费用 | 14,524,255.9 | 40,955,301.8 | 32,765,676.68 | 19,136,733.95 |
| 六、净利润 | 114,413,869.69 | 125,157,091.43 | 103,512,939.99 | -7,094,241.99 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 114,413,869.69 | 125,157,091.43 | 103,512,939.99 | -7,094,241.99 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 110,677,005.66 | 177,741,534.7 | 163,442,897.15 | 43,160,638.4 |
| 少数股东损益 | 3,736,864.03 | -52,584,443.27 | -59,929,957.16 | -50,254,880.39 |
| 扣除非经常损益后的净利润 | 113,661,365.91 | 95,450,860.28 | 70,540,034.92 | 28,442,672.68 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.07 | 0.11 | 0.1 | 0.03 |
| (二)稀释每股收益 | 0.07 | 0.11 | 0.1 | 0.03 |
| 八、其他综合收益 | - | 213,017,400 | 106,250,000 | 39,950,000 |
| 归属于母公司股东的其他综合收益 | - | 213,017,400 | 106,250,000 | 39,950,000 |
| 九、综合收益总额 | 114,413,869.69 | 338,174,491.43 | 209,762,939.99 | 32,855,758.01 |
| 归属于母公司股东的综合收益总额 | 110,677,005.66 | 390,758,934.7 | 269,692,897.15 | 83,110,638.4 |
| 归属于少数股东的综合收益总额 | 3,736,864.03 | -52,584,443.27 | -59,929,957.16 | -50,254,880.39 |
| 公告日期 | 2026-04-28 | 2026-03-28 | 2025-10-29 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |